Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2022, the compensation committee of the company’s board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company’s common stock, and granted an aggregate of 83,375 Restricted Stock Units (RSUs) to eight new(…..) Continue reading »
The Latest Press Releases